Current version snapshot

Not FDA-approved↗Safety records↗↗

Current · version 3: Epitalon↗

Related names recorded in this version: AEDG, Epithalon, Ala-Glu-Asp-Gly↗

A synthetic four-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found only a few small human reports and no studies in people with insomnia.↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked FDA’s epitalon briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists epitalon acetate. FDA has not issued a final 503A rule. 156

What this version reported

FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.↗↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

Epitalon is a synthetic four-amino-acid peptide first made in 1999. Most pharmacological studies of it come from one research group in Russia, and most of the research FDA reviewed was in animals.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved product containing it in any of the countries it checked.1 Human data are limited to a few small reports. FDA found no studies of epitalon in people with insomnia, the use it evaluated, and no clinical data supporting its safety.1 FDA staff recommended against adding epitalon to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6

At a glance

What it is
A synthetic peptide of four amino acids (Ala-Glu-Asp-Gly). FDA treats it as a different substance from epithalamin, a pineal-gland extract it was modeled on.1
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidence
A few small reports, including one 20-day randomized study that measured a melatonin breakdown product rather than sleep. FDA found no studies in people with insomnia.1
Evidence strength
Limited human data

What is epitalon?

Epitalon is a synthetic peptide made of four amino acids: alanine, glutamic acid, aspartic acid and glycine. It is also called epithalon or AEDG. It was designed from the amino-acid content of epithalamin, an extract of cattle pineal glands, but FDA treats the two as different substances.1

Epitalon appears to have been first synthesized in 1999. It received a U.S. orphan-drug designation for retinitis pigmentosa in 2010, and that designation was withdrawn in 2016.1

FDA found epitalon promoted online by wellness clinics as an anti-aging product, but could not identify any pharmacy that compounds it, and no outsourcing facility had reported compounding it.1

How is epitalon thought to work?

Because the pineal gland helps regulate the sleep-wake cycle, researchers have proposed that epitalon could affect daily body rhythms. In older female monkeys, one study reported higher evening melatonin and lower evening cortisol after treatment.1

How epitalon would change melatonin levels is unknown. A laboratory study found it did not directly increase melatonin release from rat pineal glands, and FDA found no animal studies that measured sleep itself.1

FDA’s briefing notes reports that epitalon can activate telomerase and lengthen telomeres. FDA says this raises a concern that long-term exposure could carry a cancer risk, and that the available mouse studies were too limited to rule that out.1

What do human studies show?

FDA evaluated epitalon for insomnia and found no studies of it in people with insomnia.1

The main human study FDA reviewed was a small 2021 randomized, placebo-controlled study in women working night shifts. Its authors reported that a melatonin breakdown product rose with epitalon, but the study did not measure sleep, did not state whether it was blinded, and was short.1

FDA found no clinical studies assessing epitalon’s safety and no pharmacokinetic data in people. Its searches of FDA’s adverse-event databases through December 2025 found no reports.1

FDA concluded that there is a lack of evidence that epitalon works for insomnia and no clinical data to support its safety in people.1

What the evidence base contains

  • Small, short, or incompletely reported human study A 2021 randomized, placebo-controlled study in 40 women working night shifts that measured a melatonin breakdown product over 20 days. FDA notes it did not state whether it was blinded, did not measure sleep, and did not report safety data.1
  • Small, short, or incompletely reported human study A 2002 report in people with retinitis pigmentosa, an inherited eye disease, and a meeting abstract stating that epitalon had no side effects in elderly people without giving study details.1
  • Animal or laboratory research Studies in monkeys, rats and mice reporting changes in melatonin and cortisol levels and fewer spontaneous tumors in female mice. FDA found no animal studies that measured sleep.1

Evidence-strength label: Limited human data. How this label is assigned

Is epitalon FDA-approved?

No. FDA’s May 2026 evaluation states that epitalon, in either its free-base or acetate form, is not a component of any FDA-approved drug and that there is no United States Pharmacopeia monograph for it.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5

FDA staff evaluated both forms of epitalon for that list for insomnia and recommended against adding either. They cited poor chemical characterization, a possible risk of immune reactions, no clinical safety data, a lack of evidence of effectiveness, and existing FDA-approved insomnia treatments.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists epitalon among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.3

HHS’s policy document states that epitalon was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6

FDA’s Pharmacy Compounding Advisory Committee discussed epitalon on July 24, 2026. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For epitalon, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6

HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates from FDA-registered facilities supply the quality test results FDA staff found missing, that historical use is now documented, and that FDA staff’s safety concerns are based on how epitalon might act rather than on observed harm. FDA staff had concluded that no clinical data support its safety in people.1,6

The policy does not make epitalon an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6

Timeline

  1. Epitalon appears to have been first synthesized, according to the literature FDA reviewed.1
  2. Epitalon receives a U.S. orphan-drug designation for retinitis pigmentosa. The designation was withdrawn on January 6, 2016.1
  3. Epitalon is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
  4. A Federal Register notice announces the July advisory-committee meeting that will discuss epitalon and opens a public comment docket.4
  5. Epitalon leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
  6. FDA staff date their evaluation recommending that epitalon not be added to the 503A bulks list.1
  7. FDA’s Pharmacy Compounding Advisory Committee discusses epitalon.2
  8. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists epitalon among six peptide substances used in compounding.5,6

What is still unknown?

Whether epitalon improves sleep or any other health outcome in people: FDA found no studies in people with insomnia or other conditions that measured clinical outcomes.1

Its safety in people, including with long-term use, and whether its reported effect on telomeres carries a cancer risk.1

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1

Whether FDA’s rulemaking will add epitalon to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6

Sources for this version

  1. 1
    FDA briefing document for epitalon ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026